JPM vs OPP
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe financial weakness. While the 14.14% dividend yield is superficially attractive, the payout ratio of 113.7% reveals an unsustainable distribution model that likely erodes capital. The stock is currently trading at a premium to its intrinsic value of $7.00, and a technical trend score of 0/100 confirms strong bearish momentum. Overall, the fund exhibits the characteristics of a dividend trap with deteriorating fundamentals.
Compare Another Pair
Related Comparisons
JPM vs OPP: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (OPP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.